Kurzfassung

A clinical phase II, multicenter, open-label study evaluating induction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in primary diagnosed high-risk multiple myeloma patients